Skip to main content
. 2020 Nov 3;26(4):484–502. doi: 10.1177/2472555220965528

Figure 6.

Figure 6.

Noncovalent and covalent fragment-based approaches for hit finding and ligand development for E3 ligases. (A) Initial hit compound to the final clinical compound, ASTX660.8789 (BF) Examples of specific residue-selective covalent warheads: (B) cysteine,150 (D) lysine,151 and (F) methionine;152 and (C,E,G) the reaction mechanisms.